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Abstract Quail cystatin, a new cysteine proteinase inhibitor 
protein of the cystatin superfamily, was purified from egg 
albumen of Japanese quail Coturnix coturnix japonica. Amino 
acid sequencing and mass spectrometry revealed the complete 
116 amino acid residue primary structure of a phosphorylated 
form (13173 Da). The inhibitor has a 90% sequence identity with 
chicken cystatin. Its interaction with papain is rapid and tight 
(Ki = 4.4 pM; £on = 1.8Xl0
7 M _ 1 s _ 1 ; Aoff = 0 .8xl0
 4 s_1) 
and very similar to that of chicken cystatin. Surprisingly, 
however, cathepsin B was inhibited 15-fold more strongly by 
quail cystatin (K; = 47 pM; £o n = 1 9 x l 0
7 M"1 s"1; 
&o f f=9xl0
 4 s"1) than by chicken cystatin (JEj = 784 pM; 
&on = 2.9Xl0
7 M"1 s"1; *of f=24XlO
 4 s"1). Intuitive com-
parative conformational inspection of related inhibitors and of 
cognate enzymes suggest that: (i) the 3D structure of quail 
cystatin is nearly identical to that of chicken cystatin, (ii) quail 
cystatin can interact with cathepsin B analogous to the stefin B-
papain interaction, if the 'occluding loop' of cathepsin B 
possesses an 'open' conformation, (iii) the greater inhibition of 
cathepsin B by quail cystatin compared to chicken cystatins 
probably arises from two additional ionic interactions between 
residues Arg15 and Lys112 of the inhibitor and Glu194 and Asp124 
of the enzyme, respectively. The two potential salt bridges are 
located outside of the known contact regions between cystatins 
and peptidases of the papain family. 
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1. Introduction 
Protein-type cysteine proteinase inhibitors are widely dis-
tributed in animals and plants. It is generally believed that 
these inhibitors are involved in the regulation of physiological 
and pathological processes caused by cysteine proteinases [1-
3]. Recently, we described two new proteinases from the Jap-
anese quail Coturnix corturnix japonica [4,5]. During these 
studies we detected a cysteine proteinase inhibitory activity 
comparable to that of chicken cystatm. This quail cystatin is 
described and characterized here in more detail. 
Chicken cystatin is a well characterized member of the cys-
tatin superfamily cystatin family or family 2 [6-14]. The small 
protein is a reversible, competitive, tight-binding inhibitor of 
papain. A model for its interaction with papain was proposed 
[15,16] and confirmed by the structure of the papain-stefin B 
complex [17] as well as by detailed kinetic studies of variants. 
The inhibitor N-terminal 'elephant trunk' (Leu7-Gly9) binds 
the (unprimed) specific substrate recognition sites of papain 
while the hydrophobic first (Gln53-Gly57) and second hairpin 
loops (Pro103-Leu105) bind in the broad and long U-shaped 
substrate binding cleft especially via hydrophobic contacts 
[18-25]. 
Less well understood is the interaction of cystatins with 
other cysteine proteinases like cathepsin B. The molecular 
structure of human liver cathepsin B was solved by X-ray 
analysis at 2.15 A resolution [26]. Cathepsin B exhibits both 
endopeptidase and exopeptidase activity. Cleavage of C-ter-
minal dipeptides (peptidyldipeptidase activity) is dependent on 
the presence of the specialized 'occluding loop' which presents 
C-terminal anchoring interactions; this is not present in other 
cysteine proteinases. Its occlusion of the broad substrate bind-
ing site seemed to exclude a papain-cystatin-like interaction 
because of steric clashes between it and the cystatin second 
hairpin loop. Our first cathepsin B-chicken cystatin interac-
tion model suggested that either cystatin binds to cathepsin B 
with a new geometry or that displacement of the occluding 
loop must accompany binding of cystatin to cathepsin B [26]. 
Later it was proposed that such an additional conformational 
change could explain the weaker cathepsin B inhibition by 
cystatins in general [3]. 
Recently, the tertiary structures of rat and human proca-
thepsin B were solved to shown how the proregion interacts 
with its parent protease and blocks the access to the active site 
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[27,28]. This structure demonstrated the flexibility possible for 
the 'occluding loop ' with its 'open' conformation as opposed 
to the more compact 'close conformation' found in mature 
cathepsin B [26]. 
In this paper, we describe the purification, primary struc-
ture and the inhibitory kinetics of a new cystatin. Further-
more, we present evidence for the occurrence of an 'open-
like' conformation of the occluding loop during binding of 
cystatins by cathepsin B similar as found within the proen-
zyme to occur and show that such a conformation could be 
stabilized by salt bridges formed between quail cystatin with 
cathepsin B. 
2. Material and methods 
2.1. Material 
All chemicals used were obtained from Sigma, St. Louis, MO, 
USA; Merck, Darmstadt, Germany; Serva, Heidelberg, Germany, 
and were of analytical grade. Natural chicken cystatin was a generous 
gift from V. Turk, Ljubljana, Slovenia. Human cathepsin B was pur-
chased from Medor, Herrsching, Germany and used without further 
purification. Papain was repurified as described [29]. Japanese quail 
eggs were from a random-bred strain. 
2.2. Purification of quail cystatin 
About 400 ml albumen were obtained from unbred quail eggs 
(around 100 eggs). After removing ovomucoid [12] the material was 
alkaline (pH 12) and heat (65°C) treated [11]. The resulting super-
natant (lOOOOXg, 15 min) was dialyzed and applied to a weak cation 
exchange chromatography (CM-sepharose FF, 26 X 200 mm, Pharma-
cia, 20 mM acetate buffer pH 5.5) and separated with a salt gradient 
from 0 to 0.5 M NaCl. Papain inhibitory fractions were pooled and 
adjusted to 1.2 M (NH^SC^ for a hydrophobic interaction chroma-
tography (Phenyl-Sepharose FF high substitute, 16x180 mm, Phar-
macia), elution was performed with a linear gradient to O M 
( N H ^ S O ^ The inhibitor containing fractions were concentrated 
(2 ml) and separated further by gel filtration (Superose 12, 
16x500 mm, Pharmacia). Final purification was done by cation ex-
change chromatography on a Mono S (5 X 50 mm, Pharmacia, 50 mM 
acetate buffer pH 5.5, elution by gradient from 0 to 0.5 M NaCl). 
Inhibitory fractions were pooled and stored in aliquots at —20°C. 
2.3. SDS-PAGE and determination of protein concentration 
SDS-PAGE of proteins was performed with 5-22.5% polyacryl-
amide gels [30] and protein bands were stained with silver according 
to the method of Blum [31]. Protein concentrations were determined 
by the method of Lowry et al. [32] or by absorption measurements at 
280 nM, using the extinction coefficients for aromatic residues and 
cystines of Mach et al. [33] resulting in £280 12 570 M _ 1 for the 
purified inhibitor. 
2.4. HPLC analysis and amino acid sequencing 
Purified quail cystatin samples as well as CNBr fragments or ma-
terial of tryptic digests of quail cystatin were analyzed by reversed 
phase HPLC as detailed previously [34]. Automated amino acid se-
quencing was performed using a gas-phase sequenator 473A (Applied 
Biosystems GmbH, Weiterstadt, Germany) following the instructions 
of the manufacturer. 
2.5. Mass spectrometry 
Quail cystatin and CNBr cleaved material or peptides were applied 
to a reversed phase HPLC coupled on-line to an atmospheric pressure 
ionization source fitted to the tandem quadruple instrument API III 
(Sciex, Thornhill, Ontario, Canada). The instrument m/z scale was 
calibrated with ammonium adducted ions of polypropylene glycol. 
The average molecular mass values of the proteins were calculated 
from the m/z peaks in the charge distribution profiles of the multiple 
charged ions [35]. Theoretical masses of the peptides were calculated 
with the GCG DNA/Protein Analysis Software [36]. 
2.6. Determination of kinetic constants 
Kinetic constants for the interaction of quail and chicken cystatin 
with cysteine proteinases were determined applying enzyme assays at 
30°C (papain) or 25°C (cathepsin B) and pH 5.5 with the fluorogenic 
substrate Z-Phe-Arg-NH-Mec as described [23] using 50 mM sodium 
acetate buffer. Rate constants, kon and ka[[, were obtained by pre-
steady-state analysis [37]. Equilibrium dissociation constants were 
measured directly in equilibrium inhibition experiments or calculated 
(K[ = k0glk01l) from pre-steady-state experiments and were corrected 
for substrate competition. Substrate consumption was less than 5% 
in all experiments. All calculations are based on the active concentra-
tion of the inhibitor determined by titration E-64-standardized papain 
(4 nM) and Bz-Arg-NH-Mec (10 uM) as described [34]. 
2.7. Structural inspection and modelling 
The coordinates of chicken cystatin [15], human stefin B-papain [17] 
cathepsin B [26] and procathepsin B [27] were taken from the Protein 
Data Bank [38] and displayed and manipulated using the program O 
[39]. Docking models were prepared by fitting binding site residues of 
cathepsin B, procathepsin B and chicken cystatin to the corresponding 
residues of papain in the papain stefin complex. 
3. Results 
3.1. Purification and protein chemical characterization of 
quail cystatin 
After having identified a papain inhibitory activity in the 
albumen of quail eggs [4] two classical chicken cystatin puri-
fication steps were used to enrich inhibitor: alkaline extraction 
(30 min at p H 12) and heat treatment (65°C at p H 6.0 for 
10 min) [10,11]. Affinity chromatography (with Cm-Papain-
Sepharose) did not increase the yield in active material (data 
not shown) although this step has been successfully applied 
for isolation of several other native and recombinant cystatins 
[12,24,39]. Therefore, a new purification scheme was estab-
lished comprising cation exchange chromatography (CM-
sepharose FF) , hydrophobic interaction chromatography 
(Phenyl-sepharose FF) , gel filtration (Superose 12) and cation 
exchange chromatography (Mono S). Each step was checked 
by papain inhibition tests and SDS-PAGE analyses. The pu-
rification scheme and the resulting data are given in Table 1. 
F rom 400 ml albumen 200 iig pure inhibitor were obtained, 
corresponding to an enrichment of specific activity of about 
30000-fold. The purified material migrates as a homogenous 
Table 1 
Purification of quail cystatin from albumen 
Purification step Protein (mg) Active material (units) Specific activity (units/mg) Purification (-fold) 
Homogenate 
Ovomucoid precipitation 
Heat precipitation 
CM-sepharose 
Phenyl-sepharose 
Superose 12 
Mono S 
46000 
39000 
10166 
549 
108 
1.0 
0.2 
30.3 
25.4 
18.3 
41.6 
15.7 
10.5 
4.9 
0.0007 
0.0007 
0.0018 
0.0750 
0.1450 
10.2 
23.3 
1 
3 
107 
207 
14571 
33000 
Protein was determined by the method of Lowry [31]; inhibitory activity was tested as papain inhibition with Z-Phe-Arg-NH-Mec as substrate; one 
inhibitory unit is denned as the inhibition of one unit papain activity; homogenate was obtained from 400 ml albumen. 
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Fig. 1. Amino acid sequence of quail cystatin and its tryptic and CNBr peptide map. The complete primary structure of quail cystatin is given. 
Numbers denote the positions of amino acid residues in the peptide chain of native quail cystatin. Pep tides isolated from the tryptic digest are 
identified with the prefix Tp, in ( ) brackets peptide names and in < > brackets amino acid positions are marked which were not deter-
mined. N-term. indicates the N-terminal sequenced region; CNBr-p indicates the CNBr fragments 1^1; — and -> residue identified by Edman 
degradation or last residue of a peptide; *, phosphorylated serine. 
15-kDa protein in SDS-PAGE (data not shown). H P L C anal-
yses by reverse phase chromatography confirmed the homo-
geneity of the purified inhibitor (data not shown). 
3.2. Protein sequencing and mass spectrometry 
In order to determine the complete primary structure of the 
inhibitor, we used the following overall strategy: (1) N-termi-
nal amino acid sequencing of the inhibitor; (2) tryptic cleav-
age and sequencing of selected peptides; (3) preparat ion and 
sequencing of CNBr fragments; and (4) mass determination 
of CNBr fragments and of tryptic peptides. The resulting 
primary structure of quail cystatin, schemes of sequenced pep-
tide fragments and the order of the hypothetical tryptic frag-
ments are displayed in Fig. 1. 
In more detail, N-terminal sequencing allowed the identifi-
cation of the first 38 amino acid residues. This sequence 
showed a high homology to chicken cystatin and facilitated 
the preparation, selection and identification of tryptic peptides 
in comparison to an approach performed earlier for recombi-
nant chicken cystatin [34]. The sequences of the tryptic pep-
tides TplO, T p l l , T p l 3 , T p l 4 confirmed and extended the 
high similarity to chicken cystatin. The tryptic peptides were 
aligned to chicken cystatin and a methionine substitution 
(M62) instead of L62 in chicken cystatin was identified. This 
directed us to perform CNBr cleavage. By sequencing CNBr 
fragments, the gaps between D38-Q52, R68-S74 and K109-
Q116 could be filled and the positions and sequences of the 
peptides TplO, T p l l , T p l 3 , T p l 4 overlapped and verified 
consistently (Fig. 1). In order to confirm the primary structure 
unequivocally, masses of CNBr fragments and of the purified 
inhibitor were determined (Fig. 2 and Table 2). The sequence 
correctness of non-overlapping gap borders, the C-terminus 
and the presence of the two S-S bridges (Cys n -Cys 8 1 and 
Cys95-Cys115) were deduced by these data. 
As expected, not only single masses of CNBr fragments 
containing homoserine lactone or homoserine residues (see 
Fig. 2 and Table 2, CNBr -p l , CNBr-p2, CNBr-p3) were de-
tected (mass difference of 18 Da) . Additional peptides were 
identified and their masses could be interpretated as lysine-
formylated forms (CNBr-p l , CNBr-p2, CNBr-p4 with a mass 
difference of 28 Da) or as oxidated forms of CNBr-p4 (prob-
ably first and second oxidation of Trp 1 0 8 with mass differences 
of 15 and 31, respectively). The C-terminal CNBr-p4 fragment 
did not contain a methionine but its first oxidized form 
seemed to be formylated, too (peak 3403.0, Fig. 2). Taking 
these considerations together, the detected profiles of the mass 
spectrometric measurements of all four CNBr fragments can 
be resolved unequivocally into four subgroups CNBr-p l , -p3, 
-p4 and -p2 (Fig. 2). 
The measured masses of the CNBr-p3 subgroup (E63-M89) 
differ by approx. 80 D a from the theoretical expected masses 
of a homoserine and a homoserine-lactone form. The same 
difference has been detected by mass analysis of the complete 
inhibitor. This variation is probably due to phosphorylation 
of a serine residue. Leading to a gap in Edman degradation of 
T p l 3 and the CNB3-p3 at Ser80. Therefore, it is most likely 
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Fig. 2. Mass spectrometry of CNBr-cleaved fragments of quail cystatin. The deconvoluted mass spectra gives final estimated masses of the 
main products after CNBr-cleavage. CNBr-pl-CNBr-p4 indicates the subgroups which are build by fractions of modified CNBr fragments. 
Posttranscriptional or artificial modification result in mass difference of 80 Da (phosphorylation), 16 Da (oxidation), and 28 Da (formylation). 
Numbers denoted the calculated masses from the m/z peaks in the charge distribution profiles. Bold and underlined are the homoserine lactone 
forms, in case of CNBr-p3 a possibly phosphorylated homoserine lactone form, and in case of CNBr-p4 the unmodified C-terminal fragment. 
3167.2 indicates a homoserine form, and 3177.0 a formylated homoserine lactone form of CNBr-pl; 3299.2 indicates the homoserine form of 
phosphorylated CNBr-p3, 3374.4 the first Trp-oxidized form, 3390.0 the second Trp-oxidized form, and 3403.0 the first Trp-oxidized and for-
mylated form of CNBr-p4; 3698.0 is unidentified, 3731.4 indicates the homoserine form, and 3741.8 a formylated homoserine lactone form of 
CNBr-p2. 
that quail cystatin is completely phosphorylated at Ser80. 
Whereas chicken cystatin has been found to be partially phos-
phorylated at Ser80 [41]. This is supported by the complete 
absence of an unphosphorylated peptide within the range of 
3201.5 Da (Fig. 2). 
3.3. Amino acid sequence alignment 
An alignment of the primary structures of quail cystatin, 
chicken cystatin and human cystatin C is given in Fig. 3. It 
shows an overall identity of 90% between quail cystatin and 
chicken cystatin and of 44% with human cystatin C. There are 
no sequence differences to chicken cystatin within the highly 
conserved contact regions of the cystatins, the N-terminal seg-
ment with the conserved glycine (G9), the first hairpin loop 
(QLVSG, QxVxG-region) and the second hairpin loop (PW-
region). The high sequence identity including cysteine spacing 
demonstrates clearly that quail cystatin belongs to family 2 of 
the cystatin superfamily. The identified 11 amino acid substi-
tutions as compared to chicken cystatin are distributed over 
the whole molecule but are notably absent from regions 
known to contact cysteine proteases (see below). Most re-
markable are the exchanges from basic side chains to acidic 
ones Arg15qc->Asp15cc, Lys112qc->Glu112cc and the ex-
changes from uncharged residues to an acidic one Gly3qc-
-»Asp cc or to basic ones Gin5 qc-»Arg6 cc, Ser qc-
-»Lys114cc. 
3.4. Inhibition kinetics 
Equilibrium dissociation constants (K{) were determined for 
the complexes of quail cystatin with papain and cathepsin B 
as well as for the corresponding complexes of their enzymes 
with chicken cystatin. The calculated A^-value for the papain-
quail cystatin complex is 4.4 pM and very similar to that of 
the papain-chicken cystatin complex (1.4 pM, see Table 3) 
Rate constants of complex formation (koa) and complex dis-
sociation (A:0ff) were determined in pre-steady-state experi-
ments. As shown in Table 3, the kOIi and k0g values of papain 
inhibition by chicken and quail cystatin are quite similar. 
Steady-state experiments with human cathepsin B resulted 
in a Xj-value of 47 pM. This value differs significantly from 
the published A^-values of the chicken cystatin-human cathep-
sin B complexes (0.8-2.9 nM) [12,40,41]. Therefore, we com-
pared cathepsin B inhibition of chicken and quail cystatin in 
the same set of experiments. Steady-state as well as pre-
steady-state experiments confirm the stronger inhibition of 
quail cystatin (47 pM) comparing to chicken cystatin 
(828 pM). This difference is due to a 7-fold faster association 
(kon: 19 and 2.9XlO
6 M"1 s " \ respectively) and a 3-fold 
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Fig. 3. Alignment of amino acid sequences of quail cystatin with chicken cystatin and human cystatin C. Amino acid residues are given in the 
one-letter code and numbers denote the position within quail cystatin. Sequences of chicken cystatin (Chicken cys.) are form [11] and of human 
cystatin C (Human cys. C) are from [48]. Identical residues in corresponding positions are indicated by points. The conserved contact regions 
of cystatins with glycine in the N-terminus, QLVSG in the first hairpin loop (QxVxG-region) and PW second hairpin loop are boxed. Amino 
acid residues which probably stabilize the interaction with cathepsin B outside of the conserved contact region are shaded. 
slower dissociation (k0n\ 9 and 24X1CT
3 s - 1 , respectively). 
Initially it was not clear why quail cystatin was such a strong 
cathepsin B inhibitor especially since the amino acid substitu-
tions compared to chicken cystatin were not found in regions 
known to contact cysteine proteases. Computer-aided model 
building and structural inspections suggested in particular that 
the stronger inhibition may arise from salt bridge interactions. 
3.5. Structural inspection (Modelling) 
The known crystal structures of chicken cystatin [15], hu-
Table 2 
Masses of CNBr fragments from quail cystatin 
Peptides 
cNBr-pl 
(S1-M29) 
CNBr-p2 
(A30-M62) 
CNBr-p3 
(E63-M89) 
CNBr-p4 
(A90-Q116) 
Quail cystatin* 
Theoretical mass 
3 149.5a 
3 167.5b 
3176.5C 
3 713.3a 
3 731.3b 
3 741.3C 
3201.5a 
3219.5b 
3 359.0 
3 375.0d 
3 391.0e 
3403.0f 
13 594.6 
Measured mass 
3 149.4 
3 167.2 
3177.0 
3 712.8 
3 731.4 
3 741.8 
3281.8 
3299.2 
3 359.0 
3 374.4 
3 390.4 
3403.0 
13 593.8 
A 
-0 .1 
-0 .3 
0.5 
0.5 
0.1 
0.5 
80.3 
79.7 
0.0 
-0 .6 
-0 .6 
0.0 
-0 .8 
CNBr-pl-CNBr-p4 are subgroups of CNBr-fragments, in brackets 
amino acid residues and their positions. The theoretical masses were 
determined according to [35]. Measured masses were determined as 
outlined in materials and methods. 
"S-pyridy ethylated and phosphorylated form; A, difference between 
measured mass and theoretical mass; 
Modifications: a, homoserine lactone; b, homoserine; c, formylation 
of lysine; d, oxidation of tryptophan; e, higher oxidation of trypto-
phan; f, formylation and oxidation of tryptophan. 
man cathepsin B [26]; human procathepsin B [27] and the 
stefm B-papain complex [17] were used for modelling and 
docking experiments. Substitution of the 11 amino acid side 
chains mutated in quail cystatin relative to chicken cystatin 
showed no evidence that the tertiary structure forming inter-
actions of chicken cystatin are altered; the fold is expected to 
be identical to that of chicken cystatin (Fig. 4). Furthermore, 
the docking model shows no substitutions in quail cystatin 
which should significantly alter interactions with papain com-
pared to chicken cystatin. This is consistent with the observed 
kinetic data for the papain-quail cystatin complex. 
However, because of the lack of substitutions in known 
cystatin-cysteine protease contact regions, the strong inhibi-
tion of human cathepsin B by quail cystatin was totally un-
expected. Inspection of the naive (superposition without re-
finement) docking model of cystatin immediately reveals, 
however, that two substitutions which swap negative for pos-
itive charges are positioned adjacent to acid side chains of 
cathepsin B (Figs. 4 and 5). The potential salt bridges 
(Arg15I-Glu194; Lys112I-Asp124), although accessible to sol-
vent, could contribute considerable binding energy to the in-
teraction. These interactions are not available in papain due 
to the lack of the 'occluding loop' (Asp124) and neutral resi-
dues in a different loop conformation (Glu194). 
The docking complex as depicted in Fig. 4. is unlikely due 
to the steric hindrance between the second hairpin loop of 
chicken/quail cystatin and the conformation of the 'occluding 
loop' of mature cathepsin B [26]. This conformation of the 
'occluding loop' blocks the hydrophobic/aromatic surface of 
the cathepsin B binding cleft formed primarily by residues 
Trp177 and Trp181 (papain numbering). However, the 'open-
like' conformation of the 'occluding loop' as found in proca-
thepsin B [27] is rotated approx. about the principal axis of 
the loop. This rotation frees the hydrophobic/aromatic surface 
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\ 
Fig. 4. Stereo depictions of the docking model of cystatin and human cathepsin B. The model is based on the superposition of corresponding 
binding site residues of cathepsin B and cystatin onto corresponding residues of the stefin-cathepsin B complex without further refinement. 
Side chains of mutations in quail cystatin relative to chicken cystatin are displayed in a ball and stick representation, as are disulflde bridges. 
This 'naive' docking model places two charge substitution chicken -»quail substitutions (D15-»R, E112->K) in ideal positions for salt bridge 
formation to E194 and D124 of cathepsin B, respectively. 
and expands the cleft. Minor adjustments in this loop confor-
mation and/or minor adjustments in the cystatin orientation 
(Fig. 5) would presumably allow an interaction similar to that 
of papain with stefin B [17]. The apparent lack of rigidifying 
interactions of cystatin inhibition of cathepsin B strengthen 
this hypothesis. 
4. Discussion 
Avian albumen is a source of various kinds of proteinase 
inhibitors such as ovomacroglobulin, ovomucoid, ovoinhibi-
tor and cystatin. Although chicken egg white cystatin was 
discovered already in 1968 by Fossum and Whitaker [9] no 
further avian cystatins have been described since. This paper 
reports the purification and characterization of a second avian 
cystatin, quail cystatin, which is very similar to chicken cys-
tatin from the Japanese quail Coturnix coturnix japonica. The 
cystatin concentration is rather low in the albumen of the 
quail eggs, approx. 3 |xg/ml albumen, whereas Anastasi et 
al. (1983) reported the presence of more than 80 jj.g cysta-
tin/ml in the albumen of chicken eggs [12]. This may be one 
reason why the purification of quail cystatin was not as easy 
as those of other cystatins; other reasons included the co-
migration and co-eluting fractions of lipocalin which were 
not separated in the first purification steps. 
The classical elucidation of the complete primary structure 
combined with mass spectrometry was efficient and successful. 
Conclusive interpretation of data was possible from a crude 
mixture of un-separated CNBr fragments. All prominent m/z 
peaks and their determined masses could be identified by cal-
culating and comparing well known artificial (homoserine lac-
tone, homoserine, formylations, oxidations) and posttransla-
tional modifications (phosphorylation) of the fragments. 
Furthermore, the profile shown in Fig. 2 is a nice example 
for different modified forms resulting from a CNBr cleavage 
of a small protein. 
The purified quail cystatin is completely phosphorylated at 
Ser80 according to the indirect mass and sequencing data. A 
similar but partial phosphorylation is described for chicken 
cystatin and it has been shown that this phosphorylation 
has no influence on the inhibitory activity [41]. The physio-
logical relevance of such a phosphorylation is not known. 
Undoubtedly quail cystatin is a new member of the family 2 
of the cystatin superfamily. 
Surprisingly, a significant difference was found in the inhi-
bition of human cathepsin B by quail cystatin when compared 
with other cystatins. Quail cystatin seems to be the strongest 
cathepsin B inhibitor (K\ — 48 pM) among the cystatins if 
compared with Stefin A (4-11.2 nM) [42-^14], Stefin B (16-
130 nM) [45,46], bovine parotid gland cystatin C (4.4 nM) [40] 
Table 3 
Comparison of equilibrium dissociation constants (K$ and rate constants (km 
and chicken cystatin 
and k0{{) for the inhibition of papain and cathepsin B by quail 
Inhibitor 
Quail cystatin 
Chicken cystatin 
K\ were calculated as K\ 
inhibition experiments. 
"From [19]. 
Papain 
(pmol) 
4.4 ±1.8 
1.4" 
(107 m"1 s"1) (10"4 s"1) 
1.8 ±0.4 0.8 ±0 
1.4" 0.20" 
= konlk0[[ and determined as described in Section 2. 
Cathepsin B 
(pmol) 
47±2 
828 ± 34 
Similar values were 
kon 
(106 M"1 s"1) 
19.0±2 
2.9 ±0.1 
kott 
(10~4 s"1) 
9 ± 3 
24±2 
obtained by direct evaluation of equilibrium 
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CYSTATIN 
Occluding loop 
_ _ & ■ ■ — < * . * \ ^ Lys112 
Occluding loop>J\ ' MO*Asp124 
^CATHEPSIN B G - ^ 
Occluding loop 
Procathepsin B 
\ ^-CATHEPSIN B { -
Fig. 5. Stereo view of the docking model of cystatin and human cathepsin B rotated relative to Fig. 4 showing additionally the occluding loop 
of procathepsin B. In contrast to the closed conformation of the occluding loop, only minor shifts in the occluding loop position in its open 
conformation and/or minor shifts in the cystatin orientation are required to eliminate steric clashes. 
or human cystatin C (0.17-0.26 nM) [22,48], having in mind 
that comparison of K\ values obtained under different condi-
tions is difficult. 
A strong explanation of the observed enzyme-inhibitor in-
teraction is given by computer-aided intuitive docking of the 
modelled quail cystatin molecule to the structures of cathepsin 
B and procathepsin B, assuming a stefin B-papain-like inter-
action [17] for quail cystatin-cathepsin B with an 'open-like' 
conformation of the 'occluding loop' [27] and its stabilisation 
by two possible salt bridges. 
We speculate further that for the stronger inhibition of 
cathepsin B by human cystatin C as compared to chicken 
cystatin a similar situation is present and an equivalent salt 
bridge (Asp124(catB)-Lys114) is supporting this interaction (K\ 
260 pM, [22], K{ 170 pM [48]). 
The given observations indicate that selected amino acid 
residues of the scaffold, which do not belong to the so far 
known classical contact area (N-terminus, first hairpin loop, 
second hairpin loop) of cystatin, may have distinct effects on 
inhibition and that the conformational elucidation of protein-
ase-inhibitor complexes is of great importance. 
Recently it was shown that a deletion variant of cathepsin B 
lacking 12 central residues of the 'occluding loop' is inhibited 
by human cystatin C 40-fold stronger than mature cathepsin 
B and the authors confirmed that the 'occluding loop' restricts 
access of the inhibitor to the active site [47]. Our model sug-
gest that an 'open-like' position of the 'occluding loop' is 
mandatory for effective cathepsin B inhibition. 
Further detailed interaction analyses and kinetic studies are 
necessary with cystatin and/or cathepsin B variants to test this 
hypothesis and to describe the influence of exposed amino 
acid residues during molecular interaction. 
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